Share this to:

Support & Insight for the Autumn of Life

Suvorexant Improves Sleep in Alzheimer’s

Does your loved one with Alzheimer's suffer with insomnia? Suvorexant (BELSOMRA) could help. Learn more. (Video+Article)

A medication produced by the Merck (NYSE: MRK) pharmaceutical firm, (known as MSD outside the United States and Canada) is approved by the U.S. Food and Drug Administration (FDA) for prescribing information for BELSOMRA® (suvorexant) C-IV that includes findings on the drug’s use for the treatment of insomnia in patients with mild-to-moderate Alzheimer’s disease.

Insomnia is a sleep disorder that can make it difficult to fall asleep and/or stay asleep, or it can cause people to wake up too early. Many factors contribute to insomnia, including evidence suggesting that wake-promoting signaling overrides sleep-promoting signaling in the brain.

Insomnia is more common in people with Alzheimer’s disease than in individuals who do not have Alzheimer’s disease.

BELSOMRA (suvorexant) is an all-purpose sleep drug that has also been tested in Alzheimer’s patients for safety and efficacy. It is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

The medication is a first-in-class oral orexin receptor antagonist. Orexin is a neurotransmitter found in a specific part of the brain that can help keep a person awake. The mechanism by which BELSOMRA exerts its therapeutic effect is presumed to be through antagonism of orexin receptors.

“Alzheimer’s disease is often accompanied by disruptions to an individual’s sleep-wake patterns and overall difficulty sleeping,” said Dr. W. Joseph Herring, associate vice president, Global Clinical Research, Neuroscience, Merck Research Laboratories.

“We’re pleased that the prescribing information for BELSOMRA includes findings from Merck’s first dedicated study of an insomnia medication in patients with mild-to-moderate Alzheimer’s disease.”

The findings of a randomized, double-blind, placebo-controlled, parallel-group, multi-site 4-week polysomnography trial of BELSOMRA in patients with mild-to-moderate Alzheimer’s disease were published online in Alzheimer’s & Dementia: Journal of the Alzheimer’s Association.

In the study, BELSOMRA exhibited a statistically significant improvement for both Total Sleep Time (TST) and Wake After Sleep Onset (WASO) measures, compared to those treated with placebo, as assessed objectively by polysomnography.

Adverse reactions occurring ≥2% and greater than placebo were somnolence (4% compared to 1% for placebo), dry mouth (2% compared to 1% for placebo), and falls (2% compared to 0% for placebo). The results were originally presented at the 2019 American Academy of Neurology Annual Meeting.



Notify of

Inline Feedbacks
View all comments
Hanna Levi Julian

Hanna Levi Julian

Visit Our Pages On:


This site was inspired by my Mom’s autoimmune dementia.

It is a place where we separate out the wheat from the chaffe, the important articles & videos from each week’s river of news. With a new post on Alzheimer’s or dementia appearing on the internet every 7 minutes, the site’s focus on the best information has been a help to many over the past 15 years. Thanks to our many subscribers for your supportive feedback.

The site is dedicated to all those preserving the dignity of the community of people living with dementia.

Peter Berger, Editor


Ron, a man with early-stage Alzheimer's
Alzheimer's Changes a Marriage
Ron is making the most of his early-stage Alzheimer's. See him share how he works with his wife to make their relatio...
Bob and Sue Vogel with their dog
Getting Up & Going with Early Alzheimer's
See how Bob's walking, talking, painting, getting up and going attitude makes him feel that, despite Alzheimer's, the...
Photo Of Man Sitting On A PET Scanner
Amyloid PET Scan Coverage Approved at Last
Amyloid Scans diagnose and treat Alzheimer's, at a hefty price. 11 years after FDA approval, Medicare can finally help.
Would love your thoughts, please comment.x
News, Treatments, Care Tips

Subscribe To The Weekly Newsletter

videos & articles on Research & Prevention
News to Get at the Truth

Subscribe To Our Weekly Newsletter